Norishige Iizuka
Osaka University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Norishige Iizuka.
Clinical Cancer Research | 2004
Shinji Yamamoto; Yasuhiko Tomita; Yoshihiko Hoshida; Norishige Iizuka; Shinya Kidogami; Hiroshi Miyata; Shuji Takiguchi; Yoshiyuki Fujiwara; Takushi Yasuda; Masahiko Yano; Shoji Nakamori; Masato Sakon; Morito Monden; Katsuyuki Aozasa
Purpose: Esophageal squamous cell carcinoma (ESCC) frequently shows a poor prognosis because of the occurrence of systemic metastasis, mainly via lymphatic vessels. Valosin-containing protein (VCP) has been shown to be associated with antiapoptotic function and metastasis via activation of the nuclear factor-κB signaling pathway. In the present study, we examined the association of VCP with the recurrence and prognosis of ESCC. Experimental Design: VCP expression in 156 ESCC patients [139 males and 17 females; age range, 38–82 (median, 60) years] was analyzed by immunohistochemistry. Staining intensity in tumor cells was categorized as weaker (level 1) or equal to or stronger (level 2) than that in endothelial cells. The correlation of VCP expression between the mRNA and protein levels was examined in 12 patients. Results: Fifty-seven (37.3%) cases showed level 1 and 96 (62.7%) level 2 VCP expression. Quantitative reverse transcription-PCR analysis revealed greater VCP mRNA expression in level 2 (n = 6) than level 1 cases (n = 6; P < 0.05). ESCC with level 2 expression showed higher rates of lymph node metastasis (P < 0.01) and deep tumor invasion (P < 0.01), and poorer disease-free and overall survival rates (P < 0.001 for both analyses) than ESCC with level 1 expression. Multivariate analysis revealed that VCP expression level is an independent prognosticator for disease-free and overall survival. Furthermore, VCP level was an indicator for disease-free survival in the early (pT1) and the advanced (pT2–pT4) stage groups. Conclusion: This study demonstrated the prognostic significance of VCP expression in ESCC.
Annals of Surgical Oncology | 2004
Shinji Yamamoto; Yasuhiko Tomita; Yoshihiko Hoshida; Norishige Iizuka; Morito Monden; Satoru Yamamoto; Keiji Iuchi; Katsuyuki Aozasa
Background: Valosin-containing protein (VCP; also known as p97) was shown to be associated with antiapoptosis and metastasis via activation of a nuclear factor-κB signaling pathway. Our previous study showed that the VCP expression level correlated with the disease recurrence rate and prognosis of patients with hepatocellular carcinoma and gastric carcinoma. This study was designed to evaluate the prognostic significance of VCP expression in non-small-cell lung carcinoma (NSCLC).Methods: VCP expression in 207 patients with NSCLC (133 men and 74 women) aged 35 to 78 years (median, 62 years) was examined by immunohistochemistry, in which staining intensity in tumor cells was categorized as weaker than (level 1) or equal to or stronger than (level 2) that in endothelial cells.Results: Sixty-nine (33.8%) cases showed level 1 and 135 (66.2%) showed level 2 VCP expression. The frequency of the following was higher in patients with level 2 expression than in those with level 1 expression: male sex (P < .01), histological subtype of squamous cell carcinoma (P < .05), and smoking (P < .05). Patients with level 2 expression had poorer disease-free and overall survival rates (P < .05 and P < .01, respectively) than those with level 1 expression. Multivariate analysis revealed VCP expression and pathologic T (pT) and pN classifications to be independent prognostic factors for both disease-free and overall survival and showed vascular invasion to be an independent prognostic factor for overall survival. VCP level was a prognosticator for overall survival in both the early (pT1) and advanced (pT2–3) group of the pT classification (P < .05 for both).Conclusions: The prognostic significance of VCP expression in NSCLC was demonstrated.
Annals of Surgical Oncology | 2005
Shinji Yamamoto; Yasuhiko Tomita; Takashi Uruno; Yoshihiko Hoshida; Ying Qiu; Norishige Iizuka; Itsuko Nakamichi; Akira Miyauchi; Katsuyuki Aozasa
BackgroundValosin-containing protein (VCP) is involved in the ubiquitin/proteasome-degradation pathway, which works in proliferation and antiapoptosis in human cancer cells. Our previous study showed that VCP expression levels correlated with the recurrence and prognosis of several human cancers, such as hepatocellular carcinoma, gastric carcinoma, and colorectal carcinoma. In this study, the correlation of VCP expression with the prognosis of differentiated thyroid carcinoma was examined.MethodsVCP expression in 332 patients who underwent operation for differentiated thyroid carcinoma—257 with papillary thyroid carcinoma and 75 with follicular thyroid carcinoma (FTC)—was analyzed by immunohistochemistry. The staining intensity in tumor cells was categorized as weaker than (low expression), equal to (intermediate expression), or stronger than (high expression) that in endothelial cells in noncancerous tissue.ResultsOne hundred ten (33.5%) cases showed low VCP expression, 117 (28.0%) showed intermediate expression, and 101 (30.8%) showed high expression. VCP expression significantly correlated with histological subtype (P < .05) and lymph node metastasis (P < .01). However, it correlated with neither any clinicopathologic factor nor prognosis in papillary thyroid carcinoma. VCP expression correlated with extrathyroidal extension (P < .05), pT classification (P < .05), and lymph node metastasis (P < .01) in FTC. Patients with low VCP expressing FTC showed better disease-free and overall survival rates than those with intermediate or high expression (P < .01 and P < .05, respectively). Multivariate analysis revealed VCP expression and extracapsular extension to be independent prognostic factors for disease-free survival in cases of FTC.ConclusionsThe prognostic utility of VCP expression in FTC was demonstrated.
Oncology | 2004
Shinji Yamamoto; Yasuhiko Tomita; Shoji Nakamori; Yoshihiko Hoshida; Norishige Iizuka; Jiro Okami; Hiroaki Nagano; Keizo Dono; Koji Umeshita; Masato Sakon; Osamu Ishikawa; Hiroaki Ohigashi; Katsuyuki Aozasa; Morito Monden
Objective: To determine the prognostic value of valosin-containing protein (VCP) expression and the Ki-67 labeling index (LI) in pancreatic endocrine neoplasms (PENs), the present analysis was employed. Methods: The Ki-67 LI and VCP expression at the mRNA and protein level were evaluated in 32 patients (12 male and 20 female) with PENs aged from 22 to 73 years (median 49 years). VCP staining intensity in tumor cells was categorized as weaker (level 1) or equal to stronger (level 2) compared to nontumorous islet cells. Ki-67 LI was divided into two categories: level 1, Ki-67 LI <5%, and level 2, ≧5%. Results: Five cases (15.6%) showed level 1 and 25 (84.4%) level 2 VCP expression by immunohistochemistry. A significant association was observed between VCP expression and the malignant behavior of PENs (p < 0.01). All level 1 VCP tumors were benign PENs. Quantitative reverse transcription polymerase chain reaction analysis showed higher VCP mRNA expression in malignant PENs (n = 5) than benign cases (n = 5) (p < 0.05). For Ki-67 LI, 28 cases (87.5%) showed level 1 and 4 (12.5%) level 2 expression. All patients with level 2 Ki-67 LI had metastasis. Conclusion: VCP expression analysis and Ki-67 LI are useful prognosticators for PENs.
Diagnostic Pathology | 2010
Masanori Kitamura; Naoki Wada; Shigenori Nagata; Norishige Iizuka; Yu-Fen Jin; Miki Tomoeda; Michiko Yuki; Norifumi Naka; Nobuhito Araki; Chikao Yutani; Yasuhiko Tomita
A rare case is presented of a 61-year-old man with a malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart. The primary tumor originated in the right thigh in 1982. Since then, the patient has had repeated local recurrences in spite of repeated surgical treatment and adjuvant chemotherapy. He has developed previous metastases of the lung and heart. The patient died of cardiac involvement.
Journal of Gastroenterology | 2004
Shinji Yamamoto; Yasuhiko Tomita; Yoshihiko Hoshida; Norishige Iizuka; Shigeru Marubashi; Atsushi Miyamoto; Hiroaki Nagano; Keizo Dono; Koji Umeshita; Shoji Nakamori; Masato Sakon; Katsuyuki Aozasa; Morito Monden
Previously we reported combined chemo-immunotherapy, using interferon (IFN)-α and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis. Recently, we experienced an HCC patient who died of severe interstitial pneumonia during the combined IFN-α and 5-FU therapy. This is the first report of the occurrence of interstitial pneumonia during combined IFN-α and 5-FU treatment. A 60-year-old-man was admitted to Osaka University Hospital to receive systemic chemo-immunotherapy for recurrent HCC. In the second week of the chemo-immunotherapy, he showed a decreased level of consciousness, and respiratory insufficiency. Emergency roentgenogram revealed diffuse infiltration in both lungs. Respiratory dysfunction due to interstitial pneumonia was suspected, and steroid pulse therapy was started. However, the patient showed respiratory failure, and he died 32 days after the start of the therapy. Autopsy findings showed atelectasis in the bilateral lungs, which showed elastic hard solidity and a dark red color; esophageal varices were also shown, and there was cirrhosis with a large tumor in the liver. Microscopically, the alveolar wall showed marked fibrous thickness and moderate inflammatory change, which is consistent with acute interstitial pneumonia, and the acute pulmonary change was suspected to have been the cause of death. The association of IFN with the development of interstitial pneumonia has been reported. However, the prognosis of IFN-induced interstitial pneumonia has mostly been favorable when the medication was discontinued. It has been postulated that interstitial pneumonia induced by the combination of IFN and 5-FU may be therapy-resistant. The combination of IFN-α and 5-FU is a useful therapy for patients with advanced HCC, such as that with portal vein invasion or multiple metastatic foci. Thus, interstitial pneumonia in these patients should be carefully managed.
Diagnostic Pathology | 2010
Shigenori Nagata; Yu-Fen Jin; Katsuhiko Yoshizato; Masanori Kitamura; Norishige Iizuka; Misa Song; Miki Tomoeda; Michiko Yuki; Chiaki Kubo; Hidenori Yoshizawa; Hidetatsu Outani; Kenichiro Hamada; Nobuhito Araki; Masahiro Funauchi; Yasuhiko Tomita
A case of benign mixed tumor of the soft tissue in a 64-year-old Japanese male is presented. He noticed a painless, elastic hard mass sized 3 cm in the right knee, which gradually grew larger and harder in the last 5 years. Magnetic resonance imaging demonstrated a mass lesion embedded in the subcutaneous tissue with low and high signal intensity at T1- and T2-weighted images, respectively. Tl-201 scintigraphy showed an early uptake of Tl-201 within the lesion at 10 minutes after injection, which was slightly decreased but still continued at 2 hours later. The patient underwent a resection of tumor, and the pathological diagnosis was a benign mixed tumor of soft tissue without high vascularity, characterized by histological features similar to pleomorphic adenomas in the salivary glands. Immunohistochemical study proved expression of Na+/K+-ATPase of tumor cells. Overexpression of Na+/K+-ATPase of the tumor might be responsible for the early uptake of Tl-201, and poor vascular structure in this tumor might lead to continuous accumulation. The Tl-201 scintigraphic features of mixed tumor of soft tissue are assessed to resemble those of malignant soft tissue tumors.
Annals of Surgical Oncology | 2009
Shigenori Nagata; Yu-Fen Jin; Katsuhiko Yoshizato; Miki Tomoeda; Misa Song; Norishige Iizuka; Masanori Kitamura; Hidenori Takahashi; Hidetoshi Eguchi; Hiroaki Ohigashi; Osamu Ishikawa; Yasuhiko Tomita
Annals of Oncology | 2004
Shinji Yamamoto; Yasuhiko Tomita; Yoshihiko Hoshida; S. Toyosawa; Hidenori Inohara; Mitsunobu Kishino; Mikihiko Kogo; M. Nakazawa; S. Murakami; Norishige Iizuka; S. Kidogami; Morito Monden; T. Kubo; N. Ijuhin; Katsuyuki Aozasa
Journal of The American Society of Echocardiography | 2004
Mitsuru Masaki; Tadashi Kuroda; Naoki Hosen; Hisao Hirota; Kazuo Terai; Yuichi Oshima; Yoshikazu Nakaoka; Shoko Sugiyama; Ryusuke Kimura; Satoshi Yoshihara; Manabu Kawakami; Norishige Iizuka; Yasuhiko Tomita; Hiroyasu Ogawa; Ichiro Kawase; Keiko Yamauchi-Takihara